Navigation Links
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
Date:7/30/2009

LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human antibody drug discovery company with world class expertise in targeting multi-spanning membrane proteins, announce the signature of an exclusive agreement for the development and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.

Under the terms of the agreement, Debiopharm and MSM haveformed a partnership to select antibodies against the GPCR. Upon completion of the discovery phase, MSM will grant Debiopharm a worldwide exclusive licence for the development and commercialisation of the antibody. MSM will retain marketing rights for Russia, Ukraine and several other countries in Eastern Europe and Asia. MSM will receive milestone payments from Debiopharm during the development of the product, as well as a share of royalties on net sales.

"We usually licence-in compounds with existing animal proof of concept, but we were seduced by MSM's technology and their expertise in the generation of antibodies aimed at GPCRs," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "This is a win-win situation, our companies complement one another. MSMs discovery expertise, together with our experience in drug development should lead to innovative oncology therapeutics."

"This is a transformational deal for MSM because it represents our first jointly owned program with a global partner. We are pleased to be working with Debiopharm because they are an excellent company that complements MSM's skill set. We are also happy to be among Debiopharm's partners in the antibody space," added Davis Farmer, MSM's Cha
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
2. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
3. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
4. Japanese Cancer Association and Debiopharm Honour Japanese Research
5. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
6. Debiopharm and EPFL Establish an Oncology Chair
7. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
8. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
9. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
10. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
11. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... , CANTON, Mass. and SAN DIEGO, Oct. 27 ... speak on the first night of the prestigious TEDMED ... Dr. Bates, speech "Where Does Replacement Skin Come From?" ... of Regenerative Medicine and discuss the transformation of patient ...
... Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), ... company, announced today that its Chief Financial Officer Evan ... at the BIO Investor Forum. , The presentation will ... PM PDT at The Palace Hotel in San Francisco, ...
... , NEW YORK, Oct. 27 How does ... based on invention, innovation and entrepreneurship? , (Logo: ... blogging together with real-time celebrity lectures (and required ... anything other universities have ever attempted. , ...
Cached Biology Technology:Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference 2Soligenix to Present at 8th Annual BIO Investor Forum 2Soligenix to Present at 8th Annual BIO Investor Forum 3Soligenix to Present at 8th Annual BIO Investor Forum 4NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 2NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 3NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "iPhone 5S Fingerprint Sensor ... report to their offering. ... acquisition of AuthenTec in July 2012, Apple introduced ... It is currently the only device of Apple ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... North America are a growing concern for legislators. Expanded waistlines ... disease and some cancers. One University of Alberta researcher says ... they may find that governments will throw their weight into ... Nola Ries of the Faculty of Law,s Health Law and ...
... a new nanolithography technique that is less expensive than ... with biomedical applications. "Among other things, this type ... use in biological sensors that can identify target molecules, ... medical conditions," says Dr. Albena Ivanisevic, co-author of a ...
... University School of Medicine (BUSM) has shown that a compound ... emphysema and reverse some of the damage caused by the ... cells from patients with emphysema, normal gene activity in altered ... repaired. The study, which is published in BioMed ...
Cached Biology News:Legislated to health? 2Legislated to health? 3Researchers develop new, less expensive nanolithography technique 2BUSM researchers find potential key to halt progression, reverse damage from emphysema 2BUSM researchers find potential key to halt progression, reverse damage from emphysema 3